細胞數據集合作項目
GSK 與 Relation Therapeutics 推出其 MORGAN 平台
GSK 與 Relation Therapeutics 擴大合作，共同建立大規模人體細胞數據集，並訓練人工智能模型以進行藥物標靶發現。這項合作協議價值最高達 1.1 億美元，結合 Relation 的 Lab-in-the-Loop 實驗工作流程與其 MORGAN 平台的模型，研究細胞如何回應基因變化及藥物介入。
Relation 將運用組織圖譜、單細胞及空間轉錄組學、基因定序、擾動實驗及標靶驗證等技術，並將機器學習應用於標靶識別及優先排序。這項協議延續兩家公司早前於纖維化疾病及骨關節炎領域的合作，當時雙方結合人類遺傳學、多組學及功能檢測技術。
對藥物開發商而言，這項合作突顯在模型開發的同時，生成針對特定疾病的生物數據所帶來的價值。這種做法有望減少對異質性公開數據集的依賴，同時提升人工智能輔助標靶識別及實驗驗證的效能。
英文原文
GSK and Relation Therapeutics expanded their collaboration to generate large-scale human cellular datasets and train AI models for drug target discovery. The agreement, worth up to $110 million, combines Relation’s Lab-in-the-Loop experimental workflows with models from its MORGAN platform to study how cells respond to genetic changes and drug interventions.
Relation will use techniques including tissue profiling, single-cell and spatial transcriptomics, sequencing, perturbation experiments and target validation, with machine learning applied to target identification and prioritization. The deal builds on earlier work between the companies in fibrotic diseases and osteoarthritis, where they combined human genetics, multi-omics and functional assays.
For drug developers, the partnership highlights the value of generating disease-specific biological data alongside model development. The approach could reduce dependence on heterogeneous public datasets while improving AI-supported target identification and experimental validation.
- 來源
- Trend Hunter
- 發布
- 2026-08-14
- 品類
- Newventures
- 出處
- artificialintelligence-news, relationrx